Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma

BACKGROUND: Metformin is one of the biguanides commonly used in patients with type II Diabetes Mellitus. Apart from its hypoglycemic properties, metformin also inhibits the cell cycle by restricting protein synthesis and cell proliferation via regulating the LKB1/AMPL pathway. Furthermore, it also e...

Descripción completa

Detalles Bibliográficos
Autores principales: Afzal, Muhammad Zubair, Mercado, Rima R., Shirai, Keisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027578/
https://www.ncbi.nlm.nih.gov/pubmed/29966520
http://dx.doi.org/10.1186/s40425-018-0375-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027578/
https://www.ncbi.nlm.nih.gov/pubmed/29966520
http://dx.doi.org/10.1186/s40425-018-0375-1

Ejemplares similares